BioPharma Services has completed 3 inspections this month by the U.S. FDA, with concurrent audits at both research centers in Toronto, Canada, and Columbia, MO. Over the course of 2 weeks, the back-to-back inspections focused on a total of 9 studies including 4 bioanalytical validations that were conducted in support of ANDA and NDA filings to the FDA. All 3 inspections concluded without a 483 Form being issued. BioPharma’s U.S.-based clinical facility in Columbia, MO, underwent 2 sequential ...